Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Keros Therapeutics (NASDAQ:KROS).
October 24, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Keros Therapeutics, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in Keros Therapeutics' future performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100